Purple Biotech (Israel) Today
| PPBT Stock | ILA 12.90 6.10 89.71% |
Performance0 of 100
| Odds Of DistressOver 64
|
Purple Biotech is trading at 12.90 as of the 2nd of December 2024, a 89.71 percent increase since the beginning of the trading day. The stock's open price was 6.8. Purple Biotech has more than 64 % chance of experiencing financial distress in the next few years of operation. It also generated negative returns for investors over the last 90 days. Equity ratings for Purple Biotech are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 9th of September 2023 and ending today, the 2nd of December 2024. Click here to learn more.
Purple Biotech Ltd., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs in the United States. Purple Biotech Ltd. was founded in 2010 and is headquartered in Rehovot, Israel. PURPLE BIOTECH operates under Biotechnology classification in Israel and is traded on Tel Aviv Stock Exchange. The company has 205.98 M outstanding shares. More on Purple Biotech
Moving together with Purple Stock
Moving against Purple Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
Purple Stock Highlights
Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. Purple Biotech's investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Purple Biotech or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
| Business Concentration | Biotechnology, Healthcare (View all Sectors) |
Purple Biotech (PPBT) is traded on Tel Aviv Stock Exchange in Israel and employs 5 people. The company currently falls under 'Small-Cap' category with a current market capitalization of 134.51 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Purple Biotech's market, we take the total number of its shares issued and multiply it by Purple Biotech's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities. Purple Biotech operates under Healthcare sector and is part of Biotechnology industry. The entity has 205.98 M outstanding shares.
Purple Biotech has accumulated about 48.39 M in cash with (16.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.28.
Check Purple Biotech Probability Of Bankruptcy
Purple Biotech Risk Profiles
Although Purple Biotech's alpha and beta are two of the key measurements used to evaluate Purple Biotech's performance over the market, the standard measures of volatility play an important role as well.
| Mean Deviation | 4.61 | |||
| Standard Deviation | 7.61 | |||
| Variance | 57.84 | |||
| Risk Adjusted Performance | (0.09) |
Purple Stock Against Markets
Be your own money manager
Our tools can tell you how much better you can do entering a position in Purple Biotech without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Content Syndication Now
Content SyndicationQuickly integrate customizable finance content to your own investment portal |
| All Next | Launch Module |
Purple Biotech Corporate Management
Elected by the shareholders, the Purple Biotech's board of directors comprises two types of representatives: Purple Biotech inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Purple. The board's role is to monitor Purple Biotech's management team and ensure that shareholders' interests are well served. Purple Biotech's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Purple Biotech's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MA CPA | Chief Officer | Profile | |
| Fabien Sebille | Chief Officer | Profile | |
| Michael Schickler | Head Affairs | Profile | |
| Ido Morpurgo | VP Operations | Profile | |
| Nir Livneh | VP Affairs | Profile |
Additional Information and Resources on Investing in Purple Stock
When determining whether Purple Biotech is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Purple Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Purple Biotech Stock. Highlighted below are key reports to facilitate an investment decision about Purple Biotech Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Purple Biotech. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. For information on how to trade Purple Stock refer to our How to Trade Purple Stock guide.You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.